Amy E. Miles
Known title: DirectorCIK: 0001248617
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 7, 2026
GAP Stock Mentioned in Small-Cap Watchlist Amid Valuation Focus. Gap Inc. was highlighted in a recent Yahoo Finance article as a small-cap stock worth attention, alongside two others facing headwinds. This mention comes as market focus shifts toward value metrics, with GAP currently trading at a low price-to-earnings ratio of 6.8. The stock is also near its 200-day moving average, a technical level often watched by traders for potential trend changes.
Transaction History
| AMGN | ▲ Buy | Grant | 665 | $0 | 5/19/2026 | View on chart |
| AMGN | ▲ Buy | Grant | 809 | $0 | 5/23/2025 | View on chart |
| AMGN | ▲ Buy | Grant | 719 | $0 | 5/31/2024 | View on chart |
| GAP | ▲ Buy | Option Exercise | 442 | $0 | 6/30/2023 | View on chart |
| GAP | ▲ Buy | Option Exercise | 3,126 | $0 | 6/30/2023 | View on chart |
| AMGN | ▲ Buy | Grant | 939 | $0 | 5/19/2023 | View on chart |
| GAP | ▲ Buy | Option Exercise | 27,164 | $0 | 4/1/2023 | View on chart |
| GAP | ▲ Buy | Option Exercise | 2,906 | $0 | 4/1/2023 | View on chart |
| AMGN | ▲ Buy | Grant | 855 | $0 | 5/17/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Amgen Outperforms Market Amid Dow Jones Rotation
Amgen has recently exceeded broader market returns, a trend highlighted in recent analyses of Dow Jones stocks making bullish moves during defensive market rotations. This performance contrasts with peers like Merck, where analysts are comparing dividend growth potential. While the stock shows relative strength, it remains within its 52-week range, with the average analyst target price set significantly above current levels.
Amgen Outperforms Market Amid Dow Jones Rotation. Amgen has recently exceeded broader market returns, a trend highlighted in recent analyses of Dow Jones stocks making bullish moves during defensive market rotations. This performance contrasts with peers like Merck, where analysts are comparing dividend growth potential. While the stock shows relative strength, it remains within its 52-week range, with the average analyst target price set significantly above current levels.